BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday that will take its lead candidate, acne therapy BX001, into the clinic within

Read the full 309 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE